3 completed, 3 terminated. 6 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Terminated 3 |
| Phase 2 | 1 | Terminated 1 |
Follow Urge Urinary Incontinence: new trials by email Literature Review of Urge Urinary Incontinence trials Research Report on Urge Urinary Incontinence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE) Fesoterodine Fumarate - Urge Urinary Incontinence | Phase 3 | Completed | University of North Carolina, Chapel Hill | 61 | 2012-09-01 | 2020-03-18 |
| Transcutaneous Mechanical Nerve Stimulation in the Treatment of Incontinence Transcutaneous mechanical nerve stimulation - Stress Urinary Incontinence, Urge Urinary Incontinence | Phase 3 | Terminated | Copenhagen University Hospital at Herlev | 4 | 2011-05-01 | 2013-05-24 |
| Anticholinergic vs. Botox Comparison Study Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg - Urge Urinary Incontinence, Overactive Bladder | Phase 3 | Completed | NICHD Pelvic Floor Disorders Network | 249 | 2010-03-01 | 2018-05-02 |
| Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence Oxybutynin, Placebo - Urge Urinary Incontinence, Urinary Frequency | Phase 3 | Completed | Antares Pharma Inc. | 626 | 2009-03-01 | 2014-07-02 |
| Refractory Urge Incontinence and Botox Injections Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo - Urinary Incontinence, Detrusor Overactivity | Phase 3 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 87 | 2006-06-01 | 2011-01-11 |
Urinary Incontinence, Urge (6) · Urinary Bladder, Overactive (4) · Urinary Incontinence (1) · Urinary Incontinence, Stress (1)
Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Lower Urinary Tract Symptoms (6) · Male Urogenital Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Urination Disorders (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Urological Manifestations (6) · Urinary Incontinence (5) · Urinary Bladder Diseases (4)
Botulinum Toxins, Type A (2) · Solifenacin Succinate (1) · Tolterodine Tartrate (1) · fesoterodine (1) · oxybutynin (1) · trospium chloride (1)
Antares Pharma Inc. (1) · Copenhagen University Hospital at Herlev (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · NICHD Pelvic Floor Disorders Network (1) · University of North Carolina, Chapel Hill (1) · University of Zurich (1)
United States (4) · Denmark (1) · Switzerland (1)
Anthony Visco, MD (1) · Jennifer M Wu, MD (1) · Linda Brubaker, MD (1) · Mikkel Fode, MD (1)
PMID 18499184, PMID 22008247, PMID 23036134, PMID 23218404, PMID 26516810, PMID 27564385, PMID 33620895, PMID 38651909
R03AG042335 (1), U01HD041249 (1), U10HD041250 (1), U10HD041261 (1), U10HD041267 (1), U10HD054136 (1), U10HD054214 (1), U10HD054215 (1), U10HD054241 (1)